Processa Pharma director awarded 33,500 RSUs
Processa Pharmaceuticals director Geraldine Pannu received a grant of 33,500 Restricted Stock Units on July 26, 2026.
Rhea-AI Filing Summary
Processa Pharmaceuticals director Geraldine Pannu received a grant of 33,500 Restricted Stock Units on July 26, 2026. Each RSU equals one share of common stock, vested upon grant, and will be settled at the earlier of termination, six months after grant, change of control, or death.
After this award she reports direct holdings of 38,749 RSUs, stock options for 12,000 shares at an exercise price of $4.9600, and 2,391 common shares. Reported amounts reflect the company’s 1-for-25 reverse stock split effective December 17, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 33,500 shares
Grant/Award
3 txns
Insider
Pannu Geraldine
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F1, F3 | 33,500 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) F2, F3 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 38,749 contracts (Direct);
Stock Options (Right to Buy) — 12,000 contracts (Direct);
Common Stock — 2,391 shares (Direct)
Footnotes (3)
- F1. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
- F2. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
- F3. Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
Key Figures
RSUs granted: 33,500 units
RSUs held after grant: 38,749 units
Options underlying shares: 12,000 shares
+3 more
6 metrics
RSUs granted
33,500 units
Restricted Stock Units granted to director on July 26, 2026
RSUs held after grant
38,749 units
Restricted Stock Units reported as directly owned following the grant
Options underlying shares
12,000 shares
Common shares underlying stock options held directly by the director
Option exercise price
$4.9600 per share
Exercise price for the reported stock options
Common shares held
2,391 shares
Directly owned Processa Pharmaceuticals common stock
Reverse stock split ratio
1-for-25
Reverse stock split effected on December 17, 2025
Key Terms
Restricted Stock Units, Stock Options (Right to Buy), change of control, reverse stock split
4 terms
Restricted Stock Units financial
"Each Restricted Stock Unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price of $4.9600"
change of control financial
"distributed at the earlier of termination, six months, change of control, or death"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
reverse stock split financial
"Reflects the 1-for-25 reverse stock split effected by the Issuer"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Processa Pharmaceuticals (PCSA) report for Geraldine Pannu?
Processa Pharmaceuticals reported that director Geraldine Pannu received a grant of 33,500 Restricted Stock Units (RSUs) on July 26, 2026. The RSUs vested upon grant but will be distributed later under specified conditions.
How many Restricted Stock Units does PCSA director Geraldine Pannu hold after this grant?
Following the July 26, 2026 grant, Geraldine Pannu reports direct holdings of 38,749 RSUs. Each Restricted Stock Unit represents a contingent right to receive one share of Processa Pharmaceuticals common stock, subject to the stated distribution conditions.
What are the vesting and distribution terms of the 33,500 RSUs at PCSA?
The 33,500 RSUs vested upon grant but are not distributed immediately. They will be settled at the earlier of the director’s termination, six-month anniversary of the grant date, a change of control, or the director’s death.
What stock options does PCSA director Geraldine Pannu hold?
Geraldine Pannu holds stock options over 12,000 shares of common stock with an exercise price of $4.9600 per share. These options vest one-third on the first anniversary of the grant, then ratably over the following two years.
How did the reverse stock split affect Geraldine Pannu’s reported PCSA holdings?
All reported holdings reflect a 1-for-25 reverse stock split effected on December 17, 2025. The footnote states that the share amounts shown, including RSUs and options, are presented after giving effect to this reverse split.
AI-generated analysis. How Rhea-AI works. Not financial advice.
